vs
Harmony Biosciences Holdings, Inc.（HRMY）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是Harmony Biosciences Holdings, Inc.的1.7倍（$411.1M vs $243.8M），UiPath, Inc.净利率更高（48.4% vs 9.2%，领先39.1%），Harmony Biosciences Holdings, Inc.同比增速更快（21.1% vs 15.9%），Harmony Biosciences Holdings, Inc.自由现金流更多（$126.0M vs $25.1M），过去两年Harmony Biosciences Holdings, Inc.的营收复合增速更高（25.6% vs 0.7%）
哈莫尼生物科学控股公司是一家处于商业化阶段的生物制药企业，专注于罕见神经及中枢神经系统疾病创新疗法的研发与商业化，核心产品针对发作性睡病等睡眠相关中枢神经系统病症，主要市场为美国。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
HRMY vs PATH — 直观对比
营收规模更大
PATH
是对方的1.7倍
$243.8M
营收增速更快
HRMY
高出5.2%
15.9%
净利率更高
PATH
高出39.1%
9.2%
自由现金流更多
HRMY
多$100.9M
$25.1M
两年增速更快
HRMY
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $243.8M | $411.1M |
| 净利润 | $22.5M | $198.8M |
| 毛利率 | 71.9% | 83.3% |
| 营业利润率 | 15.8% | 3.2% |
| 净利率 | 9.2% | 48.4% |
| 营收同比 | 21.1% | 15.9% |
| 净利润同比 | -54.6% | 1966.2% |
| 每股收益（稀释后） | $0.38 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HRMYPATH
| Q4 25 | $243.8M | $411.1M | ||
| Q3 25 | $239.5M | $361.7M | ||
| Q2 25 | $200.5M | $356.6M | ||
| Q1 25 | $184.7M | $423.6M | ||
| Q4 24 | $201.3M | $354.7M | ||
| Q3 24 | $186.0M | $316.3M | ||
| Q2 24 | $172.8M | $335.1M | ||
| Q1 24 | $154.6M | $405.3M |
净利润HRMYPATH
| Q4 25 | $22.5M | $198.8M | ||
| Q3 25 | $50.9M | $1.6M | ||
| Q2 25 | $39.8M | $-22.6M | ||
| Q1 25 | $45.6M | $51.8M | ||
| Q4 24 | $49.5M | $-10.7M | ||
| Q3 24 | $46.1M | $-86.1M | ||
| Q2 24 | $11.6M | $-28.7M | ||
| Q1 24 | $38.3M | $33.9M |
毛利率HRMYPATH
| Q4 25 | 71.9% | 83.3% | ||
| Q3 25 | 75.1% | 82.2% | ||
| Q2 25 | 81.0% | 82.1% | ||
| Q1 25 | 82.7% | 84.8% | ||
| Q4 24 | 73.0% | 82.0% | ||
| Q3 24 | 77.0% | 80.0% | ||
| Q2 24 | 81.4% | 83.5% | ||
| Q1 24 | 82.2% | 86.8% |
营业利润率HRMYPATH
| Q4 25 | 15.8% | 3.2% | ||
| Q3 25 | 27.3% | -5.6% | ||
| Q2 25 | 24.0% | -4.6% | ||
| Q1 25 | 30.4% | 7.9% | ||
| Q4 24 | 27.7% | -12.2% | ||
| Q3 24 | 33.2% | -32.7% | ||
| Q2 24 | 12.4% | -14.8% | ||
| Q1 24 | 33.7% | 3.7% |
净利率HRMYPATH
| Q4 25 | 9.2% | 48.4% | ||
| Q3 25 | 21.2% | 0.4% | ||
| Q2 25 | 19.8% | -6.3% | ||
| Q1 25 | 24.7% | 12.2% | ||
| Q4 24 | 24.6% | -3.0% | ||
| Q3 24 | 24.8% | -27.2% | ||
| Q2 24 | 6.7% | -8.6% | ||
| Q1 24 | 24.8% | 8.4% |
每股收益（稀释后）HRMYPATH
| Q4 25 | $0.38 | $0.37 | ||
| Q3 25 | $0.87 | $0.00 | ||
| Q2 25 | $0.68 | $-0.04 | ||
| Q1 25 | $0.78 | $0.09 | ||
| Q4 24 | $0.85 | $-0.02 | ||
| Q3 24 | $0.79 | $-0.15 | ||
| Q2 24 | $0.20 | $-0.05 | ||
| Q1 24 | $0.67 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $775.3M | $1.4B |
| 总债务越低越好 | $163.7M | — |
| 股东权益账面价值 | $870.2M | $1.9B |
| 总资产 | $1.3B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.19× | — |
8季度趋势，按日历期对齐
现金及短期投资HRMYPATH
| Q4 25 | $775.3M | $1.4B | ||
| Q3 25 | $672.6M | $1.4B | ||
| Q2 25 | $565.3M | $1.6B | ||
| Q1 25 | $507.0M | $1.6B | ||
| Q4 24 | $467.2M | $1.6B | ||
| Q3 24 | $410.5M | $1.7B | ||
| Q2 24 | $346.9M | $1.9B | ||
| Q1 24 | $372.4M | $1.9B |
总债务HRMYPATH
| Q4 25 | $163.7M | — | ||
| Q3 25 | $168.5M | — | ||
| Q2 25 | $172.1M | — | ||
| Q1 25 | $175.7M | — | ||
| Q4 24 | $179.3M | — | ||
| Q3 24 | $182.8M | — | ||
| Q2 24 | $186.4M | — | ||
| Q1 24 | $190.0M | — |
股东权益HRMYPATH
| Q4 25 | $870.2M | $1.9B | ||
| Q3 25 | $835.1M | $1.7B | ||
| Q2 25 | $773.1M | $1.7B | ||
| Q1 25 | $720.5M | $1.8B | ||
| Q4 24 | $659.2M | $1.7B | ||
| Q3 24 | $596.8M | $1.8B | ||
| Q2 24 | $538.6M | $2.0B | ||
| Q1 24 | $515.4M | $2.0B |
总资产HRMYPATH
| Q4 25 | $1.3B | $2.9B | ||
| Q3 25 | $1.2B | $2.6B | ||
| Q2 25 | $1.1B | $2.6B | ||
| Q1 25 | $1.1B | $2.9B | ||
| Q4 24 | $999.2M | $2.7B | ||
| Q3 24 | $928.1M | $2.7B | ||
| Q2 24 | $858.4M | $2.8B | ||
| Q1 24 | $847.0M | $3.0B |
负债/权益比HRMYPATH
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.2M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $126.0M | $25.1M |
| 自由现金流率自由现金流/营收 | 51.7% | 6.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.8% |
| 现金转化率经营现金流/净利润 | 5.61× | 0.14× |
| 过去12个月自由现金流最近4个季度 | $347.9M | — |
8季度趋势，按日历期对齐
经营现金流HRMYPATH
| Q4 25 | $126.2M | $28.3M | ||
| Q3 25 | $108.7M | $41.6M | ||
| Q2 25 | $79.3M | $119.0M | ||
| Q1 25 | $34.0M | $146.1M | ||
| Q4 24 | $75.6M | $28.1M | ||
| Q3 24 | $70.5M | $46.4M | ||
| Q2 24 | $42.6M | $100.0M | ||
| Q1 24 | $31.1M | $145.6M |
自由现金流HRMYPATH
| Q4 25 | $126.0M | $25.1M | ||
| Q3 25 | $108.7M | — | ||
| Q2 25 | $79.3M | $106.2M | ||
| Q1 25 | $33.9M | $138.7M | ||
| Q4 24 | $75.0M | $23.2M | ||
| Q3 24 | $70.5M | $45.0M | ||
| Q2 24 | $42.0M | $98.8M | ||
| Q1 24 | $31.1M | $141.8M |
自由现金流率HRMYPATH
| Q4 25 | 51.7% | 6.1% | ||
| Q3 25 | 45.4% | — | ||
| Q2 25 | 39.6% | 29.8% | ||
| Q1 25 | 18.3% | 32.7% | ||
| Q4 24 | 37.3% | 6.5% | ||
| Q3 24 | 37.9% | 14.2% | ||
| Q2 24 | 24.3% | 29.5% | ||
| Q1 24 | 20.1% | 35.0% |
资本支出强度HRMYPATH
| Q4 25 | 0.0% | 0.8% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 3.6% | ||
| Q1 25 | 0.1% | 1.7% | ||
| Q4 24 | 0.3% | 1.4% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.4% | 0.4% | ||
| Q1 24 | 0.0% | 0.9% |
现金转化率HRMYPATH
| Q4 25 | 5.61× | 0.14× | ||
| Q3 25 | 2.14× | 26.25× | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 0.75× | 2.82× | ||
| Q4 24 | 1.53× | — | ||
| Q3 24 | 1.53× | — | ||
| Q2 24 | 3.68× | — | ||
| Q1 24 | 0.81× | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HRMY
暂无分部数据
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
